The Regulation of Medical Devices in the UK
|
|
- Austin Bailey
- 7 years ago
- Views:
Transcription
1 The Regulation of Medical Devices in the UK 1. What are the main requirements for a medical device to enter into the market and how are they regulated? Are there any licensing, marketing authorisation, registration requirements? In the UK, medical devices are regulated by the Medical Devices Regulations 2002 (the MD Regulations ) which implement: Council Directive 90/385/EEC (active implantable medical devices), Council Directive 93/42/EEC (medical devices) and Directive 98/79/EC (in vitro diagnostic medical devices). The MD Regulations have been amended to reflect subsequent amendments to these Directives. Further, the MD Regulations also contain the necessary measures for implementation of agreements of mutual recognition between the EU and Canada, Australia, New Zealand, and the United States of America relating to medical devices. The MD Regulations set out the minimum standards for the manufacture and marketing of medical devices in the UK. The designated body for overseeing compliance with the MD Regulations is the Medicines and Healthcare Products Regulatory Agency (the MHRA ), an executive agency of the Ministry of Health. Part I of the MD Regulations contains introductory provisions relating to all types of medical devices such as definitions, the scope of the regulations and transitional provisions. Part II of the MD Regulations applies to all medical devices, accessories to medical devices, single use combination products, and systems and procedure packs, other than active implantable medical devices (and accessories thereto) and in vitro diagnostic medical devices (and accessories thereto). Those devices are dealt with in Parts III and IV respectively. According to Part II, a general medical device may not be placed on the market or put into service unless: It meets the essential requirements set out in Annex I to Directive 93/42/EEC (regulation 8); or It or its sterile pack bears a lawfully applied CE marking (regulation 10). There are exemptions to the requirements set out in regulations 8 and 10, such as devices shown at trade fairs, custom made devices, or devices intended for clinical instigations. These exemptions are given in regulation 12. The procedures for lawfully affixing a CE marking to a medical device are set out in regulation 13 (i.e. the conformity assessment procedures) by reference to relevant Annexures of Directive 93/42/EEC. There are specific arrangements which relate to systems and procedure packs, custom-made devices and devices intended for clinical investigation (regulations 14-16). The same framework is replicated in Parts III and IV of the MD Regulations for: and Active Implanted Medical Devices: essential requirements - regulations 22 and 23; exemptions - regulation 26; conformity assessment - regulations 24 and 27; specific arrangements - regulations 28 and 29; In Vitro Diagnostic Medical Devices: essential requirements - regulations 33 and 34; exemptions - regulation 39; conformity assessment - regulations 36 and 40; specific arrangements - regulation 43. However, Part III refers to Directive 90/385/EEC and Part IV refers to Directive 98/79/EC, the relevant European legislation for active implantable medical devices and in vitro diagnostic medical devices respectively.
2 The registration of medical devices is a self-declaration process. First the manufacturer (or a person who sterilises the product before it is placed on the market) must determine whether the product: falls first within the definition of a medical device and also with the definition of a Class 1 or custom-made device (regulation 19); or falls within the definition of a system or procedure pack, and is not CE marked (regulation 19); or falls within the definition of an in vitro diagnostic medical device (regulation 42). If the product falls under one of those sections, the manufacturer (or its designated person) is required to register the device with the MHRA. Registration with the MHRA is not required if the device or pack was first placed on the market in another state which is party to an association agreement, and the manufacturer has already registered with the competent authorities of the state. The data registered with the MHRA is subsequently entered into the MHRA s public access medical devices database and the European Databank on Medical Devices (EUDAMED). 2. What are the labelling and language requirements for medical devices? Do different rules apply for different types or classes of devices, i.e., medical devices for professional and non-professional use, software devices? Is e-labelling possible? As explained in Section 1, the regulation of medical devices in the UK is governed by the MD Regulations, which includes meeting certain essential requirements. Regulation 9 sets out the factors required to determine whether a general medical device complies with those essential requirements and in particular sub-paragraph (3) details the mandatory labelling requirements by cross reference to Annex I to Directive 93/42/EEC. However, the MD Regulations specify that the essential requirements (set out in paragraphs 8.7 and 13 of Annex I to Directive 93/42/EEC) regarding information on the package or label are only complied with if the information is in English (regardless of whether it is also present in another language or whether the device is for professional use). The essential requirements concerning information which must be supplied by the manufacturer are as follows: Labelling to distinguish between sterile and non-sterile products (paragraph 8.7). Information required to use the device safely and properly (paragraph 13.1). Labelling detailing: the name and address of the manufacturer or authorised representative; words to identify the device; a batch or serial number; a use before date or if not appropriate the date of manufacture; any special operating instructions; any necessary warnings or precautions to be taken; and where appropriate the words STERILE (paragraph 13.3). If the intended purpose of the device is not obvious to the user, it must be clearly stated on the label and on the instructions for use (paragraph 13.4). The essential requirements, regarding instructions for use are only complied with if: (i) the instructions are in English or another Community language; and (ii) if the instructions are not in English, any packaging, label or insert carries a clear statement in English stating the language in which the instructions are given. The essential requirements concerning the particulars which must be included in the instructions for use are as follows (paragraph 13.6): Save for batch numbers and dates; the information referred in paragraph 13.3 (discussed above). Performances referred to in paragraph 3 and any side effects. Details of any further treatment before the device can be used. Information needed to verify whether the device is properly installed. Information on processes for re-use (if applicable). Information detailing any contraindications or precautions to be taken. Date of issue of the instructions for use.
3 The requirements for active implantable medical devices and in vitro diagnostic medical devices are dealt with by a similar framework, albeit set out in regulations 23 and 35 in Parts III and IV respectively. In the case of active implantable medical devices, sub-paragraph (3) of regulation 23 specifies the following mandatory labelling requirements: The essential requirements in paragraph 14 of Annex I to Directive 90/385/EEC, regarding information on the package or label, will only be complied with if the information is in English (regardless of whether it is in another language or whether device is for professional use). The essential requirements in paragraph 13 of Annex I to Directive 90/385/EEC, regarding instructions for operation of the device in paragraph 15 of Annex I, will only be complied with if: (i) the instructions are in English or another Community language; and (ii) if the instructions are not in English, any packaging, label or insert carries a clear statement in English stating the language in which the instructions are given. In the case of in vitro diagnostic medical devices, sub-paragraph (2) of regulation 35 details the following mandatory labelling requirements: The essential requirements in paragraph 8 of Part B if Annex I to Directive 98/79/EC, regarding information to be provided, are only complied with if that information is in English and only to the extent that the device may reach a consumer in the United Kingdom. 3. What are the main rules and principles for advertising of medical devices and interactions with health care professionals and to what extent do they differ from the ones applicable to pharmaceuticals? The MD Regulations do not cover separate advertising materials only the labelling and packaging of medical devices themselves. Advertising materials are instead regulated in part under general consumer protection legislation such as the Sale of Goods Act 1979 (as amended) and the Consumer Protection from Unfair Trading Regulations 2008; and in part under the advertising regulatory regime administered by the Advertising Standards Association ( ASA ). The latter regime is set out in two advertising codes: Broadcast advertising must comply with the UK Code of Broadcast Advertising ( BCAP Code ); with medical devices and medicines subject to the specific provisions of Rule 11. Rule 11 includes the requirements that any marketing communication must be centrally cleared before being broadcast and that marketing for any claims must be evidenced. Non-broadcast advertising must comply with the UK Code of Non-broadcast Advertising, Sales Promotion and Direct Marketing ( CAP Code ); with medical devices and medicines subject to the specific provisions of Rule 12. Rule 12 again addresses numerous aspects of marketing communications including the requirements for any claims to be evidenced, not to mislead consumers by using confusing language, and not to guarantee the efficacy or safety of products. The advertising of medicines is considerably more heavily regulated than that of medical devices and must comply with the requirements of the Medicines Act 1968 as well as the BCAP and CAP Codes. The Medicines Act requirements include compliance with regulations made under it as well as any conditions contained in the marketing authorisation, certificate, licence or traditional herbal registration for the product being advertised. Further, Title VIII of European Directive 2001/83/EC, as amended by Directive 2004/27/EC, concerns The Advertising of Medicinal Products for Human Use and has been implemented in the UK by The Medicines (Advertising) Regulations 1994 and The Medicines (Monitoring of Advertising) Regulations 1994 (both as amended). These Regulations have been incorporated into the CAP and BCAP Codes.
4 4. To what extent the pricing and reimbursement of medical devices are regulated? Under what conditions will the costs of the medical devices be reimbursed and by which competent authority? In the UK, the pricing of medical devices is not regulated, with manufacturers being free to set their own prices. However, if a device is also within the definition of a pharmaceutical product (e.g. diagnostic imaging contrast agents) then it will fall within the ambit of the Pharmaceutical Price Regulatory Scheme ( PPRS ), a voluntary agreement entered between the Department of Health and the pharmaceutical industry and renewed every 5 years or so. In essence the PPRS limits the amount of profit a company can make from sales of branded medicines to the UK s National Health Service ( NHS ) by seeking to balance the objectives of, on the one hand, ensuring the supply of safe, effective medicines to the NHS and, on the other, ensuring the pharmaceutical industry is sufficiently profitable to be capable of sustained research and development. If the manufacturer does not join the PPRS, then a mandatory statutory scheme applies. As regards reimbursement, there is no simple answer. There is no national list detailing which devices are specifically reimbursable or at what price. Instead medical devices are reimbursed through a coding system called Healthcare Research Groups ( HRGs ). HRGs are annually reviewed groupings of clinically similar treatments that use similar levels of resources. An HRG code is given to each such treatment group and that code is then used to determine the level of reimbursement that should be provided based on the resources that have been used. In addition, pass-through payments may also be available for innovative devices in certain circumstances. Where devices do not fall within an HRG, local agreements are put in place to determine their reimbursement status. 5. What are the main rules applicable to clinical trials of medical devices? The rules relating to clinical trials of medical devices are contained in the MD Regulations. Its regulations 16 and 29 set out parallel regimes for clinical trials for general medical devices and active implantable medical devices respectively. Both regimes require an application to be made to the MHRA before a trial can commence. The manufacturer of the device must, not less than 60 days before the commencement of the proposed trial, notify the competent authority of its intention to undertake a clinical trial of a non-ce marked medical device. The notification in relation to a general medical device must include a statement containing the information required by Annex VIII of Council Directive 93/42/EEC which includes: Detailed information relating to the device and manufacturer; Clinical investigation plan, investigators brochure, confirmation of insurance and documents used to obtain informed consent; Research ethics committee opinions; A statement that the device conforms with the essential requirements set out in Annex I of Council Directive 93/42/EEC; and An undertaking to keep information available for the Secretary of State for a minimum period of five years. These requirements are more or less mirrored in the statement required for active implantable medical devices which are set out in Section 2.2 of Annex 6 to Council Directive 90/385/EEC. Unless the MHRA notifies the manufacturer otherwise, the clinical trial may proceed after the 60 day notification period has elapsed. However, in practice the MHRA generally issues a notice informing the manufacturer that it may proceed at, or within, the 60 days. The MHRA may also attach conditions to a notice, such as a requirement to obtain a favourable opinion from its ethics committee before the trial can proceed. Further, the MHRA may withdraw a notice at any time. After withdrawal no further clinical use may be made of the device. Once a manufacture has received permission to proceed it must conduct the clinical trial in accordance with: Annex X of Council Directive 93/42/EEC for general medical devices; or Annex 7 of Council Directive 90/385/EEC for active implantable medical devices.
5 Finally, the manufacturer has a duty to notify the MHRA of the end of the clinical trial and to provide justification where a trial is ended prematurely. The procedures for in vitro diagnostic devices differ from those for general medical devices and active implantable medical devices in that clinical trials are not necessary. Instead a performance evaluation is required (regulation 43 of the MD Regulations). Before the manufacturer can register a device for performance evaluation he must: prepare a statement containing the information referred to in Section 2 of Annex VIII of Directive 98/79/EC; ensure that the device conforms with documentation mentioned in Section 2 of Annex VIII of Directive 98/79/EC and that the relevant requirements of Directive 98/79/EC are complied with; and undertake to keep available documentation allowing an understanding of the design, manufacture and performances of the device for 5 years after the performance evaluation. Registration with the MHRA is not required if the device was first placed on the market in another state which is party to an association agreement, and the manufacturer has already registered with the competent authorities of the state. Simon Spink & Ralph Cox Fasken Martineau LLP 30 January 2014 This questionnaire is Fasken Martineau s contribution to BioLegis survey of medical devices regulation in 15 European countries, including Israel and Turkey. Biolegis is a network of leading independent European law firms with strong expertise in life sciences, including biotechnology, pharmaceuticals, medical devices and related fields of law. For more information, visit
2002 No. 618 CONSUMER PROTECTION. The Medical Devices Regulations 2002
STATUTORY INSTRUMENTS 2002 No. 618 CONSUMER PROTECTION The Medical Devices Regulations 2002 Made - - - - - 20th May 2002 Laid before Parliament 21st May 2002 Coming into force - - 13th June 2002 ARRANGEMENT
More informationGuidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC
Guidance on the In Vitro Diagnostic Medical Devices Directive 98/79/EC August 2013 Contents 1 Introduction...3 2 Scope of the directive...3 2.1 What is an in vitro diagnostic medical device?... 3 2.2 Specimen
More informationGUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES
GUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES Foreword This guidance document is informative and advisory and has no legal authority. Individual national enforcement authorities are bound
More informationDESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
More informationMedical Devices. Notified Bodies and the CE certification Process for Medical Devices. European Surgical Robotics Demonstration Day
Medical Devices Notified Bodies and the CE certification Process for Medical Devices European Surgical Robotics Demonstration Day 27 th March 2014, Leuven, Belgium 1 Bart Mersseman Product Manager Medical
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationGUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES
Foreword GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES These guidance notes do not aim to be a definite interpretation of National Laws and/or regulations and are for guidance purpose only.
More informationMedical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules?
Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules? CEMO Congress, Paris, February 3rd, 2011 Dr. Martine Dehlinger-Kremer Vice President Global Regulatory Affairs Agenda
More information(OJ L 169, 12.7.1993, p. 1)
1993L0042 EN 11.10.2007 005.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 concerning
More informationDRAFT FOR CONSULTATION. Homeopathic Medicines: Guidance on advertising
DRAFT FOR CONSULTATION Homeopathic Medicines: Guidance on advertising 1. Purpose of this Guideline This guidance has been developed by the Medicines and Healthcare products Regulatory Agency (MHRA) in
More informationManual for ITC's clients, 2013. Conformity assessment of ACTIVE IMPLANTABLE MEDICAL DEVICES pursuant to Council Directive 90/385/EEC
Manual for ITC's clients, 2013 Conformity assessment of ACTIVE IMPLANTABLE MEDICAL DEVICES pursuant to Council Directive 90/385/EEC Institute for Testing and Certification, inc., Czech Republic, EU 1.
More informationUpdate: Proposed Medical Device Regulation (MDR) & IVD Regulation (IVDR)
Update: Proposed Medical Device Regulation (MDR) & IVD Regulation (IVDR) Paul Brooks Healthcare Solutions Disclaimer The new regulations are not finalized and subject to change http://medicaldevices.bsigroup.com/en-us/resources/whitepapers-and-articles/
More informationMEDICAL DEVICES INTERIM REGULATION
Issued by the Saudi Food and Drug Authority Board of Directors decree number 1-8-1429 and dated 27 December 2008 The Interim was published in Umm Al-QURA Journal year 86 Issue No:4249 dated in 17 April
More informationEmerging Device Topics for Regulatory Consideration.. Janine Jamieson May 2015
Emerging Device Topics for Regulatory Consideration. Janine Jamieson May 2015 Disclaimer These are my personal views and not necessarily those of MHRA as an organisation. 2 European regulation of combination
More informationTHE PROMO OF MEDICAL DEVICES IN THE EUROPEAN UNION. February 2010 SPECIAL REPRINT. By Elisabethann Wright, oussanov
February 2010 SPECIAL REPRINT UNDERSTANDING THE PROMO OMOTION OF MEDICAL DEVICES IN THE EUROPEAN UNION By Elisabethann Wright, Fabien Roy and Alexander Roussano oussanov Reproduced with the kind permission
More informationA Revised EMC Directive from Europe
TÜV America Inc. Phone: (978) 739-7000 5 Cherry Hill Drive Fax: (978) 777-8441 Danvers, MA 01923 E-mail: info@tuvam.com www.tuvamerica.com A Revised EMC Directive from Europe INTRODUCTION The Commission
More informationAn introduction to the regulation of apps and wearables as medical devices
An introduction to the regulation of apps and wearables as medical devices Introduction Phones are increasingly equipped with a range of devices capable of being used as sensors, including gyroscopes,
More informationThe Act on Medical Devices
The Act on Medical Devices The Act on Medical Devices of 2 nd August 1994 (Federal Law Gazette I, p. 1963), in the version of 7 th August 2002 (Federal Law Gazette I, p. 3146), last amended by Article
More informationMedical Devices. IRELAND Arthur Cox
Medical Devices IRELAND Arthur Cox CONTACT INFORMATION Colin Kavanagh Arthur Cox Earlsfort Centre Earlsfort Terrace Dublin 2, Ireland +353.1.618.0548 Colin.Kavanagh@arthurcox.com www.arthurcox.com 1. Definition
More informationSafeguarding public health The Regulation of Software as a Medical Device
Safeguarding public health The Regulation of Software as a Medical Device Dr Head of New and Emerging Technologies Medicines and Healthcare Products Regulatory Agency (MHRA) Crown Copyright 2013 About
More informationAdvertising of medicines: Guidance for providers offering medicinal treatment services
Appendix 6 Advertising of medicines: Guidance for providers offering medicinal treatment services 1. Purpose This guidance has been developed by the Medicines and Healthcare products Regulatory Agency
More informationGuide for Custom-Made Dental Device Manufacturers on Compliance with European Communities (Medical Devices) Regulations, 1994
Guide for Custom-Made Dental Device Manufacturers on Compliance with European Communities (Medical SUR-G0014-1 12 NOVEMBER 2013 This guide does not purport to be an interpretation of law and/or regulations
More informationVOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/BL D(2002) NOTICE TO APPLICANTS Revision 3 VOLUME 2A Procedures for marketing authorisation CHAPTER 1
More informationBSI Unannounced Audits
BSI Unannounced Audits Frequently Asked Questions (FAQs) BSI Group Kitemark Court, Davy Avenue Knowlhill, Milton Keynes MK5 8PP, United Kingdom T: +44 845 080 900 Certification.sales@bsigroup.com bsigroup.com
More informationHow To Know If A Mobile App Is A Medical Device
The Regulation of Medical Device Apps Prepared for West of England Academic Health Science Network and University of Bristol June 2014 June 2014 1 Table of Contents 1 Purpose...3 2 Scope...3 3 The Regulation
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
More informationClaims Management Services Regulation. Conduct of Authorised Persons Rules 2013 (2)
Claims Management Services Regulation Conduct of Authorised Persons Rules 2013 (2) Effective from 8 July 2013 Contents Introduction 1 Definitions 1 General Rules Principles 2 Conduct of Business 2 Professional
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal
More information2016 No. 375 COMPANIES. The European Public Limited-Liability Company (Register of People with Significant Control) Regulations 2016
S T A T U T O R Y I N S T R U M E N T S 2016 No. 375 COMPANIES The European Public Limited-Liability Company (Register of People with Significant Control) Regulations 2016 Made - - - - 15th March 2016
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationRECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
More informationCE Marking: Your Key to Entering the European Market
CE Marking: Your Key to Entering the European Market N. Gerard Zapiain U.S. Department of Commerce International Trade Administration Office of Microelectronics, Medical Equipment and Instrumentation I.
More informationCouncil 23 July 2014 Consultation on draft Professional Indemnity Insurance Rules
10 Council 23 July 2014 Consultation on draft Professional Indemnity Insurance Rules Classification Purpose Issue Public For decision GOsC is required to make changes to its Professional Indemnity Insurance
More informationMEDICAL DEVICE GUIDANCE
May 2014 MEDICAL DEVICE GUIDANCE GN-23: Guidance on Labelling for Medical Devices PREFACE This document is intended to provide general guidance. Although we have tried to ensure that the information contained
More informationGuidelines on endorsement as a nurse practitioner
Guidelines on endorsement as a nurse practitioner 7160 Introduction The National Registration and Accreditation Scheme (the National Scheme) for health professionals in Australia commenced on 1 July 2010
More informationGuidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
More informationLICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002
Fax: 020 7273 0121 To all licence holders and representative associations Dear Sir/Madam Our Ref: MLX/277 15 November 2001 LICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002
More informationWant to know more about the Notified Body?
NBG/V 2/07/14 BSI Notified Body (0086) Kitemark Court Davy Avenue Knowlhill Milton Keynes MK5 8PP United Kingdom T: +44 845 080 9000 E: eu.medicaldevices@bsigroup.com W: medicaldevices.bsigroup.com Want
More informationThe Regulation of Unfair Practices in TV and Radio Advertisements
The Regulation of Unfair Practices in TV and Radio Advertisements BCAP Consultation Document Issued: 24 June 2008 Closing date for responses: 22 July 2008 2 The Regulation of Unfair Practices in TV and
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationCOMMISSION DIRECTIVE 2003/94/EC
L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
More informationUNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES
UNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES A WHITE PAPER ON THE REQUIREMENTS, REGULATIONS AND OPPORTUNITIES CONTAINED IN EC DIRECTIVE 98/79/EC AND A BRIEF COMPARISON
More informationDocument Title: Trust Approval and Research Governance
Document Title: Trust Approval and Research Governance Document Number: SOP034 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationClinical trials regulation
Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update
More informationDECISIONS ADOPTED JOINTLY BY THE EUROPEAN PARLIAMENT AND THE COUNCIL
L 218/82 EN Official Journal of the European Union 13.8.2008 DECISIONS ADOPTED JOINTLY BY THE EUROPEAN PARLIAMENT AND THE COUNCIL DECISION No 768/2008/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of
More informationHaving regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
More informationPre-market Information - Class III and IV
Pre-market Information - Class III and IV Life Sciences Council British Columbia NRC Industry Research Assistance Program Vancouver, October 29, 2007 Mary-Jane Bell, Ph.D. Medical Devices Bureau (MDB)
More informationBERMUDA TRUSTS (REGULATION OF TRUST BUSINESS) EXEMPTION ORDER 2002 BR 38 / 2002
QUO FA T A F U E R N T BERMUDA TRUSTS (REGULATION OF TRUST BUSINESS) EXEMPTION ORDER 2002 BR 38 / 2002 TABLE OF CONTENTS 1 2 3 4 5 6 7 8 Citation Interpretation Exemption in connection with private trust
More informationGUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DIRECTORATE GENERAL for HEALTH and CONSUMERS Consumer Affairs Health technology and Cosmetics MEDDEV 2.12/2 rev2 January 2012 GUIDELINES ON MEDICAL DEVICES POST MARKET CLINICAL FOLLOW-UP
More informationThe Electricity and Gas (Internal Markets) Regulations 2011
STATUTORY INSTRUMENTS 2011 No. 2704 ELECTRICITY GAS The Electricity and Gas (Internal Markets) Regulations 2011 Made - - - - 9th November 2011 Coming into force in accordance with regulation 1(1) 26.75
More informationInvestigational Testing Requirements
Investigational Testing Requirements Life Sciences Council British Columbia NRC Industry Research Assistance Program Vancouver, October 29, 2007 Mary-Jane Bell, Ph.D. Medical Devices Bureau (MDB) Therapeutic
More informationEuropean Regulatory Newsletter July - September 2013
European Regulatory Newsletter July - September 2013 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree
More informationGUIDELINES ON MEDICAL DEVICES. IVD GUIDANCES : Borderline issues A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single Market : regulatory environment, standardisation and New Approach Pressure equipment, medical devices, metrology MEDDEV. 2.14/1 rev. 1 January
More informationTHE CLAIMS MANAGEMENT CODE ( the Code )
THE CLAIMS MANAGEMENT CODE ( the Code ) CONTENTS 1 Introduction 2 Principles 3 Publishing the Code 4 Training and Competence 5 Advertising, Marketing and Promotional Activities 6 Charges 7 Information
More informationInsurance Companies INSURANCE COMPANIES (REINSURANCE DIRECTIVE) REGULATIONS 2007
Legislation made under s. 118 of the Insurance Companies Act. INSURANCE COMPANIES (REINSURANCE DIRECTIVE) by Act 2009-17 as from 9.4.2009 (LN. ) Commencement 20.12.2007 Amending enactments None Relevant
More informationFairtrade Standards for UK Operators. Part 2 (of 6) General registration requirements
Fairtrade Standards for UK Operators In six parts Part 2 (of 6) General registration requirements These requirements are relevant to all companies registered with the Fairtrade Foundation and include:
More informationGUIDELINES FOR IMPORT AND MANUFACTURE OF MEDICAL DEVICES
GUIDELINES FOR IMPORT AND MANUFACTURE OF MEDICAL DEVICES The Ministry of Health and F.W. under Gazette notification S.O. 1468 (E) dated 6/10/2005 declared the following sterile devices to be considered
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationGuide to The Notification System for Exempt Medicinal Products
Guide to The Notification System for Exempt Medicinal Products AUT-G0090-1 10 JULY 2014 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationAUTHORISATION JAMES PAGET UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
AUTHORISATION of JAMES PAGET UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (pursuant to Section 6 of the Health and Social Care (Community Health and Standards) Act 2003) Signature:... 1 August 2006 1 TABLE
More informationLegal and governance framework
Annex A Legal and governance framework This annex is a brief guide to the legal and governance framework relevant to research in the UK. It is not intended to be a comprehensive statement of the law or
More information2011 No. 1824 TOWN AND COUNTRY PLANNING. The Town and Country Planning (Environmental Impact Assessment) Regulations 2011
STATUTORY INSTRUMENTS 2011 No. 1824 TOWN AND COUNTRY PLANNING The Town and Country Planning (Environmental Impact Assessment) Regulations 2011 Made - - - - 19th July 2011 Laid before Parliament 26th July
More informationWork plan for GMP/GDP Inspectors Working Group for 2016
21 December 2015 EMA/INS/GMP/738756/2015 Compliance and Inspection Work plan for GMP/GDP Inspectors Working Group for 2016 Chairperson: Status David Cockburn January 2016 1. Meetings scheduled for 2016
More informationClaims Management Services Regulation. Conduct of Authorised Persons Rules 2014
Claims Management Services Regulation Conduct of Authorised Persons Rules 2014 Effective from 1 October 2014 Contents Introduction 1 Definitions 1 General Rules Principles 2 Conduct of Business 2 Professional
More informationGuidance on UK medical education delivered outside the UK. Introduction. Purpose of guidance
Guidance on UK medical education delivered outside the UK Introduction Purpose of guidance 1. The purpose of the General Medical Council (GMC) is to protect, promote and maintain the health and safety
More informationSMALL AND MEDIUM SIZED BUSINESS (CREDIT INFORMATION) INSTRUMENT 2016
SMALL AND MEDIUM SIZED BUSINESS (CREDIT INFORMATION) INSTRUMENT 2016 Powers exercised by the Financial Ombudsman Service FCA 2016/17 A. The Financial Ombudsman Service Limited makes and amends the Voluntary
More informationClinical evaluation Latest development in expectations EU and USA
Clinical evaluation Latest development in expectations EU and USA Medical Devices: staying ahead of regulatory developments Gert Bos BSI Israel 22 April - Herzliya Copyright 2012 BSI. All rights reserved.
More information2016 No. 0000 FINANCIAL SERVICES AND MARKETS. The Central Securities Depositories Regulations 2016
Consultation draft November 2015. S T A T U T O R Y I N S T R U M E N T S 2016 No. 0000 FINANCIAL SERVICES AND MARKETS The Central Securities Depositories Regulations 2016 Made - - - -... 2016 Laid before
More informationDonepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationGuidance on legislation. Clinical investigations of medical devices guidance for manufacturers
Clinical investigations of medical devices guidance for manufacturers November 2013 Contents Clinical investigation in the UK: requirements of the legislation... 3 Is a clinical investigation required:
More informationFrequently Asked Questions. Unannounced audits for manufacturers of CE-marked medical devices. 720 DM 0701-53a Rev 1 2014/10/02
Frequently Asked Questions Unannounced audits for manufacturers of CE-marked medical devices 720 DM 0701-53a Rev 1 2014/10/02 What is an unannounced audit?... 6 Are unannounced audits part of a new requirement?...
More informationCMD(v)/GUI/014. GUIDANCE for The Processing of Generic Applications Through MRP / DCP
EMEA/CMDv/262452/2008 GUIDANCE Edition number : 00 Edition date: 19 June 2008 Implementation date : 04 July 2008 CMD(v) Secretariat: 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74
More informationEnergy Products (Safety and Efficiency) Regulations 2012
Version: 10.5.2012 South Australia Energy Products (Safety and Efficiency) Regulations 2012 under the Energy Products (Safety and Efficiency) Act 2000 Contents 1 Short title 2 Commencement 3 Interpretation
More informationSTATUTORY INSTRUMENTS. 2015 No. FINANCIAL SERVICES AND MARKETS. The Payment Accounts Regulations 2015 DRAFT. Made - - - - ***
Draft Order laid before Parliament under paragraph 2(2) of Schedule 2 to the European Communities Act 1972, for approval by resolution of each House of Parliament. STATUTORY INSTRUMENTS 2015 No. FINANCIAL
More informationTHE LICENSING OF PENSION ENTITIES IN PRIVATE PENSION SYSTEMS
THE LICENSING OF PENSION ENTITIES IN PRIVATE PENSION SYSTEMS July 2007 This comparative report provides background to the OECD-IOPS Guidelines on the Licensing of Pension Entities. For further on this
More information7 IX. Equity (EEA Prospectus Directive) this is provisionally deleted pending review
ICMA PRIMARY MARKET HANDBOOK (IPMA HANDBOOK) Section Seven Standard Documentation & Standard Language 7 IX Standard Form Selling Restrictions A B Debt (UK) Equity (EEA Prospectus Directive) this is provisionally
More informationQUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September
More informationPlanning Act 2008: Guidance on Changes to Development Consent Orders. December 2015 Department for Communities and Local Government
Planning Act 2008: Guidance on Changes to Development Consent Orders December 2015 Department for Communities and Local Government Crown copyright, 2015 Copyright in the typographical arrangement rests
More informationAS TABLED IN THE HOUSE OF ASSEMBLY
AS TABLED IN THE HOUSE OF ASSEMBLY A BILL entitled INSURANCE AMENDMENT ACT 2014 TABLE OF CONTENTS 1 2 3 4 5 6 7 8 9 10 11 12 13 Citation Inserts section 15A Amends section 17A Amends section 30JA Amends
More informationThe Blue Guide ADVERTISING AND PROMOTION OF MEDICINES IN THE UK
The Blue Guide ADVERTISING AND PROMOTION OF MEDICINES IN THE UK Third Edition First revision - September 2014 MHRA CONTACT POINTS FOR ADVICE ON ADVERTISING AND PROMOTION OF MEDICINES The Advertising Standards
More informationLondon Metal Exchange. Jurisdictions
London Metal Exchange Jurisdictions United Kingdom The Exchange is a recognised investment exchange under the Financial Services and Markets Act 2000 and permitted to make electronic access to LME Select
More informationProposals for the reform of the regulation of unlicensed herbal remedies in the United Kingdom made up to meet the needs of individual patients
Proposals for the reform of the regulation of unlicensed herbal remedies in the United Kingdom made up to meet the needs of individual patients Summary of responses to consultation document MLX299 January
More informationCare Act 2014 CHAPTER 23. Explanatory Notes have been produced to assist in the understanding of this Act and are available separately
Care Act 2014 CHAPTER 23 Explanatory Notes have been produced to assist in the understanding of this Act and are available separately 23. 25 Care Act 2014 CHAPTER 23 CONTENTS PART 1 CARE AND SUPPORT General
More informationChanges to Medical Device Regulations
Changes to Medical Device Regulations How these will affect distributors? IMSTA Breakfast Briefing, 24 October 2013 Niall MacAleenan Medical Device Lead, IMB. Slide 1 Content Revision of the medical device
More informationINTERNAL REGULATIONS
COUNCIL OF BUREAUX CONSEIL DES BUREAUX INTERNAL REGULATIONS Preamble (1) Whereas in 1949 the Working Party on Road Transport of the Inland Transport Committee of the Economic Commission for Europe of the
More informationANNEX F. Organic agriculture (Art. 11) ARTICLE 1. Objectives
ANNEX F Organic agriculture (Art. 11) ARTICLE 1 Objectives Without prejudice to their obligations with regard to products not originating in the Member States or other legislative provisions in force,
More informationDraft guidance for registered pharmacies preparing unlicensed medicines
Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies
More informationPutting Consumers First. Code of Practice. 2014 The Professional Financial Claims Association. All rights reserved.
Putting Consumers First Code of Practice 2014 The Professional Financial Claims Association. All rights reserved. Introduction The members of the Professional Financial Claims Association (PFCA) wish to
More informationFINANCIAL SERVICES BOARD
BOARD NOTICE 102 OF 2004 FINANCIAL SERVICES BOARD FINANCIAL ADVISORY AND INTERMEDIARY SERVICES ACT, 2002 (ACT NO. 37 OF 2002) NOTICE ON SPECIFIC CODE OF CONDUCT FOR AUTHORISED FINANCIAL SERVICES PROVIDERS
More information2015 No. 2059 PROFESSIONAL QUALIFICATIONS. The European Union (Recognition of Professional Qualifications) Regulations 2015
S T A T U T O R Y I N S T R U M E N T S 2015 No. 2059 PROFESSIONAL QUALIFICATIONS The European Union (Recognition of Professional Qualifications) Regulations 2015 Made - - - - 17th December 2015 Laid before
More informationMEDICAL DEVICES SECTOR
MEDICAL DEVICES SECTOR MDS - G1 GUIDANCE FOR MEDICAL DEVICE IMPORTERS Version 2 Our mission is to ensure the safety of food; the safety, quality and efficacy of drugs; and the safety and effectiveness
More informationLicence condition handbook
Licence condition handbook January 2016 Office for Nuclear Regulation page 1 of 24 The standard licence conditions attached to nuclear site licences Introduction This booklet has been produced as an aide-memoire
More informationSummary of the role and operation of NHS Research Management Offices in England
Summary of the role and operation of NHS Research Management Offices in England The purpose of this document is to clearly explain, at the operational level, the activities undertaken by NHS R&D Offices
More informationConformity assessment certification
TGA use only This form, when completed, will be classified as 'For official use only'. For guidance on how your information will be treated by the TGA see: Treatment of information provided to the TGA
More informationFood supplements. Summary information on legislation relating to the sale of food supplements
Food supplements Summary information on legislation relating to the sale of food supplements 1 This guidance applies to the whole of the UK and was prepared by the Department of Health in association with
More informationStandard conditions of the Electricity Distribution Licence
Gas and Electricity Markets Authority ELECTRICITY ACT 1989 Standard conditions of the Electricity Distribution Licence Statutory Consultation: 29 April 2008 SECTION A: STANDARD CONDITIONS FOR ALL ELECTRICITY
More information